Corcept Therapeutics Incorporated (CORT) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: revenue growth and strategic expansion in pharmacy capacity are positive, but the significant drop in net income and lack of priority review for the ovarian cancer NDA are concerns. The Q&A reveals confidence in handling increased volume and no downward pressure on margins, but management's vague responses on certain issues may worry investors. The market cap is moderate, suggesting a neutral stock price movement, balancing positive growth prospects with current financial challenges.
Key Financial Performance
Revenue $207.6 million in Q3 2025, up from $182.5 million in Q3 2024, reflecting a year-over-year increase. The increase is attributed to robust growth in the hypercortisolism business, driven by a record number of prescriptions for Korlym and an expanded base of prescribers.
Net Income $19.7 million in Q3 2025, down from $47.2 million in Q3 2024, reflecting a significant year-over-year decrease. The decline is due to factors not explicitly detailed in the transcript but may include increased operational costs or investments.
Cash and Investments $524 million as of September 30, 2025. This reflects the acquisition of $50 million of common stock under the stock repurchase program and shares acquired through stock option exercises and restricted stock vesting.
Hypercortisolism Business Growth 42.5% increase in tablets shipped in Q3 2025 compared to Q3 2024, driven by record prescriptions for Korlym and an expanded prescriber base. Growth was partially constrained by insufficient capacity of the previous pharmacy vendor, prompting a transition to a new pharmacy.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Relacorilant for hypercortisolism: FDA approval expected by December 30, 2025. Supported by pivotal Phase III GRACE trial and other studies showing significant health improvements.
Relacorilant for ovarian cancer: FDA approval expected by July 11, 2026. European regulatory decision likely by year-end 2026. Supported by ROSELLA trial showing improved survival rates.
Miricorilant for MASH: Phase IIb MONARCH study results expected by late 2026. Early studies showed rapid reduction in liver fat and improved liver health markers.
Dazucorilant for ALS: Phase III trial to start by mid-2026. Phase II trial showed 84% reduction in risk of early death.
Hypercortisolism awareness: Growing physician awareness due to studies like CATALYST, showing higher prevalence and effective treatment options.
Oncology market expansion: New studies targeting broader range of solid tumors, including pancreatic, cervical, and endometrial cancers.
Pharmacy network expansion: Transitioning to a new pharmacy in Q4 2025 to address capacity constraints. Adding two more specialty pharmacies in 2026.
Sales force expansion: Increased sales team from 60 to 150 clinical specialists to support hypercortisolism awareness and product adoption.
Oncology development strategy: Expanding beyond ovarian cancer to other solid tumors. Initiating multiple Phase II studies to broaden treatment applications.
ALS and MASH focus: Advancing trials for dazucorilant in ALS and miricorilant in MASH, targeting significant unmet medical needs.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Patent litigation with Teva Pharmaceuticals: Corcept is involved in ongoing patent litigation with Teva Pharmaceuticals regarding the marketing of a generic version of Korlym. A court ruling against Corcept in December 2023 has been appealed, and the outcome remains uncertain. If Corcept loses, it could face significant revenue loss due to generic competition.
Pharmacy capacity constraints: The company has faced insufficient capacity from its previous pharmacy vendor, which has impacted its ability to meet growing demand for Korlym. While transitioning to a new pharmacy, capacity constraints may persist for the next few months, potentially affecting revenue and customer satisfaction.
Regulatory approval risks: Corcept has two new drug applications (NDAs) pending FDA approval, with PDUFA dates in late 2025 and mid-2026. Delays or rejections could significantly impact the company's strategic plans and revenue projections.
Market competition: The company faces competition from other medications, including new diabetes drugs like Ozempic and Mounjaro, which could limit the market share for its hypercortisolism treatments.
Economic and operational risks in oncology expansion: Corcept is expanding its oncology program into new areas, including earlier lines of therapy and new tumor types. This expansion involves significant investment and operational complexity, with no guarantee of success or market adoption.
Dependence on clinical trial outcomes: The company has several ongoing clinical trials, including MOMENTUM, ROSELLA, BELLA, and MONARCH. Negative or inconclusive results could hinder product approvals and market expansion.
Supply chain and scalability challenges: As demand for its products grows, Corcept anticipates that even its new pharmacy network may eventually face capacity issues, necessitating further expansion and investment.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company has modified its 2025 revenue guidance to $800 million to $850 million.
Pharmacy Transition and Expansion: The company is transitioning to a new pharmacy in Q4 2025 to address capacity constraints and plans to add a second specialty pharmacy in January 2026 and a third shortly thereafter to meet growing demand.
Relacorilant Revenue Projections: Relacorilant is expected to generate $3 billion to $5 billion in annual revenue in hypercortisolism alone within the next 3 to 5 years.
FDA Approvals and PDUFA Dates: The company expects FDA approval for relacorilant for hypercortisolism by December 30, 2025, and for platinum-resistant ovarian cancer by July 11, 2026. A European regulatory decision for ovarian cancer is expected by year-end 2026.
Clinical Trial Results Timelines: Results from the MOMENTUM trial (resistant hypertension) and ROSELLA trial (platinum-resistant ovarian cancer) are expected in early 2026. Results from the BELLA trial (advanced ovarian cancer) and MONARCH trial (MASH) are expected by the end of 2026.
ALS Phase III Trial: A Phase III trial for dazucorilant in ALS is planned to start by mid-2026, aiming to replicate strong Phase II results.
Oncology Program Expansion: The company is initiating multiple new oncology studies, including Phase II trials for relacorilant in combination with other therapies for various cancers, with first results expected by the end of 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Stock Repurchase Program: Our cash and investments at September 30 were $524 million, which reflects our acquisition of $50 million of our common stock in the third quarter pursuant to our stock repurchase program as well as shares acquired upon the exercise of Corcept stock options and the vesting of restricted stock grants.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How many patients were on the drug at the end of the quarter?
A:There were around 3,250 paying patients at the end of the third quarter.
Q:What is the capacity and experience of the new distributor onboarded in October?
A:The new distributor has 25 years of experience in serving orphan and orphan disease products. They have the ability to expand with the business and have multiple locations around the country for distribution.
Q:Are there plans to add more pharmacies for distribution?
A:Yes, there are plans to add second and third pharmacies to handle the expected increase in market capacity, especially with the launch of relacorilant in 2026.
Q:Are there any downward pressures on gross margins due to increased volume, pricing, or generic shifts?
A:No, there have been no downward pressures on gross margins, and none are expected.
Q:What is the net pricing relative to brand pricing, and how much of the business is coming from the authorized generic (AG)?
A:About two-thirds of the business was on the authorized generic in the second quarter, which increased to the low 70% range in the third quarter. It is expected to reach around 75% by the end of the year. The net pricing is about a 30% discount to Korlym's list price.
Q:Why was a priority review not received for the ovarian cancer NDA?
A:The company requested a priority review but did not receive it. They were confident in meeting the criteria for substantial benefit in terms of safety or efficacy, but the FDA's decisions are sometimes opaque and influenced by their priorities.
Q:What are the expectations for R&D and SG&A expenditures in 2026?
A:R&D expenditures are expected to remain the same as in 2025, while SG&A expenses are expected to increase due to investments in launches for relacorilant in hypercortisolism and ovarian cancer.
Q:Is the second pharmacy, Curant, fully operational, and can it handle the increased volume?
A:Yes, Curant is fully operational as of October 1, taking new patients and transitioning the remainder of the business over the quarter. The company is confident in Curant's ability to handle the increased volume.
Q:Has there been a late-cycle review for relacorilant, and what can be shared?
A:Yes, both mid-cycle and late-cycle reviews have been conducted as per the FDA's schedule. The company cannot comment on the specifics but is confident the FDA will meet its target date of December 30.
Q:Is Optime still selling Korlym, and for how long?
A:Yes, Optime is still servicing patients as per their contractual obligations.
Q:How does the company plan to achieve the required 28% growth in Q4 sales with only one pharmacy?
A:The company clarified that they have two pharmacies, with Optime servicing the active patient base and Curant handling new prescriptions. They expect combined efficiencies and a strong Q4.
Q:What is nenocorilant, and how does it differ from relacorilant?
A:Nenocorilant is a new molecule with unique properties suitable for regular dosing and combination with PD-1 inhibitors in solid tumors. It is considered a better partner for PD-1 inhibitors compared to relacorilant. Preclinical data is expected to be published next year.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details about the late-cycle review for relacorilant, citing confidentiality. Additionally, the response regarding the lack of priority review for the ovarian cancer NDA was vague, attributing it to the FDA's opaque decision-making process.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO Director
Co Founder
Founder President
GR antagonism
GR antagonist
II study
II trial
NDA treatment
PDUFA date
Phase II
President CEO
awareness hypercortisolism
capacity pharmacy
cortisol receptor
court decision
date NDA
demand
goal
guideline
insight
investigator
journal
nab pac
oncology program
order
pac bevacizumab
pac patient
patient cancer
patient platinum
patient tumor
prevalence hypercortisolism
receptor antagonism
result trial
treatment woman
tumor GR
type tumor
world
CORT Transcript
Corcept Therapeutics Incorporated (CORT) Q1 2026 Earnings Call Transcript
Unknown5-1
The earnings call presents mixed signals. Financial performance shows revenue growth but a significant net loss. Product updates are promising, with positive trial results and optimistic guidance for Cushing's syndrome and oncology drugs. However, operational challenges, regulatory risks, and competitive pressures persist. The Q&A reveals confidence in relacorilant and Lifyorli but highlights market competition and supply chain issues. No share buyback or dividend program is mentioned. Considering the market cap and mixed outlook, the stock price is likely to remain stable, with a neutral sentiment over the next two weeks.
Corcept Therapeutics Incorporated (CORT) Q4 2025 Earnings Call Transcript
Positive2-24
The company's earnings call highlights strong revenue growth, a successful stock repurchase program, and strategic pharmacy transitions to meet demand. Despite a decline in net income, the optimistic guidance and potential FDA approvals for relacorilant support a positive outlook. The Q&A section reveals confidence in resolving supply chain issues and potential new oncology standards. However, uncertainties with the FDA and price erosion concerns slightly temper the sentiment. Given the market cap, the stock is likely to react positively, with a predicted movement of 2% to 8% over the next two weeks.
Corcept Therapeutics Incorporated (CORT) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call presents a mixed picture: revenue growth and strategic expansion in pharmacy capacity are positive, but the significant drop in net income and lack of priority review for the ovarian cancer NDA are concerns. The Q&A reveals confidence in handling increased volume and no downward pressure on margins, but management's vague responses on certain issues may worry investors. The market cap is moderate, suggesting a neutral stock price movement, balancing positive growth prospects with current financial challenges.
Corcept Therapeutics Incorporated (CORT) Q2 2025 Earnings Call Transcript
Positive8-1
The earnings call summary and Q&A reveal strong revenue growth, a strategic sales force expansion, and a promising drug pipeline. Despite minor setbacks in pharmacy capacity impacting financial results, the company's stock repurchase program and optimistic future revenue expectations, particularly for relacorilant, are positive indicators. The Q&A also highlighted management's proactive measures to address pharmacy issues and expand market reach. With a market cap of $3.3 billion, the stock is likely to see a positive movement of 2% to 8% over the next two weeks.
CORT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
